Institut für Krebsforschung, University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Abbreviations: BSA, bovine serum albumin; Cox-1, cyclooxygenase type I; Cox-2, cyclooxygenase type II; DMSO, dimethylsulphoxide; EGF, epidermal growth factor; GSTp, placental glutathione S-transferase; GSTp, hepatocytes negative for placental glutathione S-transferase; GSTp+, hepatocytes positive for placental glutathione S-transferase; LI, labelling index; NNM, N-nitrosomorpholine; PB, phenobarbital; PG, prostaglandin; PPAR, peroxisome proliferator activated receptor
; TBS, Tris-buffered saline; TGF
, transforming growth factor
; TGF
, negative for transforming growth factor
; TGF
+, positive for transforming growth factor
.
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Rat liver offers an excellent tool for mechanistic studies on all stages of hepatocarcinogenesis. When applying placental glutathione S-transferase (GSTp) as marker, putatively initiated GSTp-positive (GSTp+) single cells are detectable a few days after treatment with various genotoxic carcinogens, such as N-nitrosomorpholine (NNM) (10,11). A portion of these cells develops to preneoplastic GSTp+ foci, some of which evolve into adenomas and carcinomas (1214). From the 2-cell stage onwards GSTp+ foci exhibit elevated rates of cell replication and cell death by apoptosis; this elevated cell turnover increased even further in hepatocellular adenomas and carcinomas (13,15). Tumour promoters, such as phenobarbital (PB) and the progestin cyproterone acetate, or increased food intake led to preferential inhibition of apoptosis of preneoplastic liver cells, thereby accelerating the selective growth of the lesion (1618). This indicates enhanced sensitivity of preneoplastic cells to endogenous tumour promoters. The reasons for the enhanced sensitivity of liver preneoplasia and the identity of endogeneous tumour promoters are still known only partially (19,20). Recently preneoplastic liver cells at a very early stage of development have become available for investigation in vitro (21). This model, in combination with studies in vivo, has been used here to investigate the mechanisms underlying the growth advantage of preneoplastic hepatocytes.
PGs are important growth regulators in the liver of rats and humans, e.g. PGE2 and PGF2 are stimulatory for hepatocyte proliferation, while inhibitory effects have been attributed to PGA2, PGJ2 and PGD2 (2225). The significance of PGs for hepatocarcinogenesis in rats has become evident in experiments with inhibitors of the key enzymes of PG synthesis, cyclooxygenase type I (Cox-1) and cyclooxygenase type II (Cox-2). Both Cox-1 and Cox-2 are inhibited by indomethacin, acetylsalicylic acid and other `classical' non-steroidal anti-inflammatory drugs, while a new generation of anti-inflammatory drugs, including SC236, has been developed to selectively affect Cox-2 (2628). Non-steroidal anti-inflammatory drugs reduce proliferation of cultured hepatoma cells, inhibit the progression from G1 to S phase and may also induce apoptosis (29). Several studies documented a chemopreventive effect of non-steroidal anti-inflammatory drugs in rat hepatocarcinogenesis. Acetylsalicylic acid reduced the number and size of GSTp+ preneoplastic foci in the liver of rats fed a choline-deficient diet (30,31). In the post-initiation phase acetylsalicylic acid also antagonized growth promotion of GSTp+ foci by PB or acetylaminofluorene (3234).
The mechanisms by which non-steroidal anti-inflammatory drugs inhibit hepatocarcinogenesis remain to be clarified. Evidence is increasing that in the liver PGs interfere with the network of other growth factors, such as epidermal growth factor (EGF) and transforming growth factor (TGF
) (23,25,35,36). EGF and TGF
are functionally and structurally related peptides (37). They are produced by several tissues in demand for cell replication and are secreted outside the cell, where they may bind to and activate the EGF receptor, which transfers the signal via phosphorylation cascades to the nucleus. During hepatocarcinogenesis in experimental animals and in humans TGF
is synthesized by (pre)malignant cells and seems to stimulate tumour growth by an autocrine loop (3841). Transgenic mice overexpressing TGF
in the liver develop hepatocellular carcinoma with high incidence and multiplicity (4244). We have recently shown that TGF
is already overexpressed in the first stages of hepatocarcinogenesis and is associated with enhanced DNA synthesis (45).
PGs have been found to regulate the effects of exogenous EGF and TGF on DNA synthesis in cultured hepatocytes (22). During regenerative liver growth PGs are produced locally (46,47). No data are available on the roles PGs and TGF
may play in the proliferation advantage of early prestages of liver cancer. Therefore, the following questions were investigated: (i) is intracellular TGF
involved in the enhanced DNA replication of preneoplastic cells; (ii) do PGE2/F2
and PGA2/J2 modify TGF
expression and DNA synthesis of unaltered and preneoplastic hepatocytes; (iii) do Cox inhibitors reduce DNA synthesis and TGF
expression in unaltered and preneoplastic hepatocytes? To tackle these questions unaltered and preneoplastic GSTp+ cells were studied in rat liver in vivo and in our newly developed cell culture model (21). The results suggest that: (i) TGF
expression plays a key role in the enhanced growth of preneoplastic GSTp+ hepatocytes; (ii) GSTp+ cells overexpressing TGF
do not require additional stimulation of DNA synthesis by PGE2/F2
but are the target of suppression of DNA synthesis by PGA2/J2 and by the Cox-2 inhibitor SC236. This supports the concept that Cox-2 inhibition may be of benefit for prevention of liver tumours.
![]() |
Materials and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Immediately after treatment the daily food consumption decreased from 15.9 ± 1.0 to 3.6 ± 0.5 g at day 3 and gradually recovered to 15.9 ± 1.1 g on the following days. On days 4, 5 and 6 after NNM treatment PB (Fluka AG, Buchs, Switzerland) was dissolved in tap water and administered by gavage as a dose of 50 mg/10 ml/kg body wt at the end of the daily feeding period at 3 p.m. From day 7 onwards, when the animals had regained their normal food intake, PB was mixed with the powder diet (Altromin 1321N) and PB concentrations were adjusted every 14 days to provide a daily dose of 50 mg/kg body wt. Controls were fed the basal diet ad libitum, since PB treatment did not alter food intake or body weight (not shown). Animals were killed by decapitation under CO2 narcosis. Time points of killing were 8, 14, 20, 51, 91 and 266 days post-NNM treatment. The experiment was performed according to Austrian guidelines for animal care and protection.
Histology
Specimens of liver tissue were fixed in paraformaldehyde and were processed as described (15). Four serial sections, 2 µm thick, were cut; one of the sections was stained for TGF, the second for GSTp, the third for Cox-1 and the fourth for Cox-2.
Immunostaining for GSTp, TGF, Cox-1 and Cox-2
The primary antibodies used were: rabbit polyclonal IgGs raised against the Yp subunit of the rat enzyme (Biotrin International, Dublin, Eire); mouse monoclonal IgG raised against recombinant mature TGF (originally clone 213-4.4; Oncogene Science, Uniondale, NY); goat polyclonal IgG raised against the C-terminus of rat Cox-1 (C-20; Santa Cruz Biotechnology, Santa Cruz, CA); mouse monoclonal IgG raised against purified sheep Cox-1(Cayman Chemical, Ann Arbor, MI); goat polyclonal IgG raised against the N-terminus of rat Cox-2 (N-20; Santa Cruz); mouse monoclonal IgG raised against C-terminal amino acids 368604 of rat Cox-2 (clone 33; Transduction Laboratories, Lexington, KY). The following schedule was used: hydrogen peroxide to block endogenous peroxidases (3%) for 20 min at room temperature; 2.5% bovine serum albumin (BSA) in Tris-buffered saline (TBS) (0.05 M Tris, 0.3 M NaCl, pH 7.6) for 30 min at room temperature; incubation overnight at 4°C with primary antisera diluted in 2.5% BSA/TBS (anti-Yp, 1:5000; anti-TGF
, 1:50; mouse anti-Cox-1 and mouse anti-Cox-2, 1:50; goat anti-Cox-1 and goat anti-Cox-2, 1:100); rinsing with TBS; incubation for 90 min at room temperature with secondary antisera diluted in BSA/TBS [biotinylated goat anti-rabbit IgG, 1:600 (Dakopatts, Glostrup, Denmark); biotinylated rabbit anti-mouse IgG, 1:600 (Dakopatts); biotinylated mouse anti-goat IgG, 1:200 (Sigma)]; rinsing with TBS; addition of streptavidinhorseradish peroxidase conjugate (1:300 in TBS; Dakopatts) for 45 min at room temperature; colour development with diaminobenzidine. The specificity of immunohistochemistry was confirmed by omitting the primary antibodies.
Quantitative evaluation of GSTp+ foci
GSTp+ single cells and GSTp+ multicellular foci were identified with an anti-GSTp stain. The number of all foci consisting of at least five GSTp+ cells per cross-section were registered; the number of GSTp+ cells per focus cross-section was counted.
Primary hepatocyte cultures
Male Wistar rats were treated with a single dose of NNM (250 mg/kg body wt) as described above. Twenty-one days later livers were perfused with collagenase according to the technique of Seglen (48), with modifications as described (21,49). Before perfusion the processus papilliformus caudatus of the liver was tied and cut off for histology (see above for details).
Treatment of primary hepatocyte cultures
Petri dishes (3.5 cm diameter; NUNC, Roskilde, Denmark) were coated with diluted collagen (1:10 in distilled water). Cells were seeded at a densitiy of 30 000 viable cells/cm2 in 2 ml of William's E2 medium plus 10% foetal calf serum and were incubated at 37°C in an incubator with 5% CO2 in air at 98% relative humidity. After an attachment period of 1 h the monolayers were rinsed with medium and were left in 1.5 ml of serum-free Williams E2 medium for 23 h to recover from the isolation stress.
PGE2, PGF2, PGA2 and PGJ2 were obtained from Biomol (Plymouth Meeting, PA). PGE2, PGF2
and PGJ2 were dissolved in 100% ethanol (100 mM stock for PGE2 and PGF2
; 50 mM stock for PGJ2). PGA2 was obtained as a solution in 100% acetone; the acetone was evaporated under liquid nitrogen and the remnant was dissolved quickly in 100% ethanol to produce a stock of 100 mM. Immediately before treatment stock solutions were further diluted in medium and aliquots were added to achieve the final concentrations. Indomethacin (Sigma) was diluted in 100% ethanol to give a 50 mM stock. In all treated and control groups the final concentration of ethanol was 0.1% in the medium. SC236 (4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide), generously supplied by Searle (Seattle, WA), was dissolved in dimethylsulphoxide (DMSO) to give a 20 mg/ml stock; 1 µl of a stock of recombinant human TGF
(10 µg in 10 µl of 10 mM acetic acid; UBI, Lake Placid, NY) was added per ml medium; tyrphostin A25 (synonym tyrphostin AG82; Calbiochem, La Jolla, CA) was prepared as a stock solution of 10 mg in 1 ml of DMSO and was added to the medium to a final concentration of 20 µg/ml; the concentration of DMSO in the medium of all groups, including the controls, was 0.2%. Treatment commenced 4 h after plating (time point 0 in the experimental protocol). Treatment with PGs and indomethacin was renewed with a medium change after 20 h. SC236 was applied only once, 4 h after plating, and the medium change 20 h later was omitted.
Double immunostaining for GSTp and TGF
Cells in culture were fixed for 90 min at room temperature with 4% buffered formalin according to Lillie and were then kept in distilled water at 4°C until immunostaining. Then the following schedule was used: hydrogen peroxide to block endogenous peroxidases (3%) for 20 min at room temperature; primary antibodies diluted in 2.5% BSA in TBS (rabbit anti-GSTp, 1: 5000; mouse-anti-TGF, 1:50) applied overnight at 4°C; rinsing with TBS; secondary antibodies diluted in 2.5% BSA/TBS [biotinylated goat-anti-mouse IgG, 1:600 (Dakopatts); alkaline phosphatase-labelled goat anti-rabbit] applied for 90 min at room temperature; rinsing with TBS; incubation with streptavidinhorseradish peroxidase conjugate (1:300 in TBS; Dakopatts) for 45 min at room temperature; colour development with diaminobenzidine (Sigma) and nitro-blue tetrazolium salt/5-bromo-4-chloro-3-indolylphosphate. The specificity of immunohistochemistry was confirmed by omitting both primary antibodies or anti-TGF
and anti-Yp only.
Double immunostaining for GST-P and Cox-1/Cox-2
The protocol exactly followed the procedure for double immunostaining for GSTp and TGF except for the following modifications: anti-GSTp (anti-Yp, 1:500) and anti-Cox-1 or anti-Cox-2 (both 1:100; Santa Cruz Biotechnology) were applied together; alkaline phosphatasemouse anti-rabbit antibody conjugate (1:100; Sigma) was applied, followed by biotinylated rabbit anti-goat antibody (1:200; Dakopatts) and horseradishstreptavidin conjugate; colour development as described above. The specificity of immunohistochemistry was confirmed by omitting both primary antibodies or anti-GSTp or anti Cox-1/anti Cox-2 only.
Determination of DNA replication and apoptosis in cultures
Newly synthesized DNA was labelled with [3H]thymidine (sp. act. 60 80 Ci/mmol; ARC, St Louis, MO), which was added at 0.5 µCi/ml medium 24 h before harvesting.
Immunohistochemically stained plates (see above) were coated with 1% gelatin, 0.05% chromalaun, air dried and were then dipped into Ilford K5 photoemulsion (Ilford, Dreieich, Germany). Time of exposure was on average 24 h. Immediately after autoradiography plates were stained for 5 min with 8 µg/ml Hoechst 33258 (Riedel de Haen, Seelze, Germany) in phosphate-buffered saline, followed by two washes with distilled water. The plates were dried at room temperature and mounted in Kayser's glycerin gelatin (Merck, Darmstadt, Germany).
For determination of DNA synthesis a total of 1000 GSTp-negative (GSTp) and TGF-negative (TGF
), 200300 GSTp+ and 300400 TGF
-positive (TGF
+) hepatocytes were evaluated per plate. Labelling index (LI) was calculated as percentage labelled hepatocyte nuclei of total number of hepatocyte nuclei counted. For evaluation of apoptosis at least 1000 hepatocyte nuclei per plate were scored for apoptotic morphology (condensed and fragmented nuclei) under a fluorescence microscope as described (50). The percentage of apoptotic bodies was calculated (apoptosis index).
Statistics
Routinely between four and six equally treated hepatocyte cultures per rat were run and harvested in parallel. If not stated otherwise, the means ± SD (vertical lines) of three cultures from at least three different donor rats are given. The significance of differences of means was tested either by Wilcoxon's test, the paired t-test or the KruskalWallis test.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Treatment with the initiating carcinogen NNM induced GSTp+ preneoplastic foci in rat liver. A sub-group of animals received the potent tumour promoter PB from day 4 post-NNM onwards. As a result, the size of the foci expanded dramatically (data not shown), as described previously (16,31,40).
At day 91 post-NNM 25% of the GSTp+ foci in control or PB-treated rats contained TGF+ cells, which occurred at a frequency of ~10% within the lesion. TGF
+ foci were significantly larger than TGF
foci without and with tumour promotion by PB (Figure 1
).
|
|
Expression of GSTp, TGF, Cox-1 and Cox-2 in hepatocellular carcinoma
After NNM and 260 days of PB treatment liver tumours had developed. Fifteen of 16 GSTp+ hepatocellular carcinomas studied (93%) contained TGF+ cells at a frequency of nearly 100% (Figure 2F
); 63 and 50% of the tumours expressed Cox-1 and Cox-2 at an extent similar to the perivenous tissue, respectively; the remaining tumours exhibited reduced levels (Figure 2G and H
).
Expression of GSTp, TGF, Cox-1 and Cox-2 in hepatocytes in primary culture
On days 2022 post-NNM livers were perfused with collagenase to isolate and cultivate hepatocytes. To evaluate the reliability of the in vitro culture system we determined the percentages of GSTp+ and TGF+ hepatocytes in tissue sections of a liver lobe left intact at perfusion and after 48 h in culture (see Materials and methods): the mean frequencies of GSTp+ hepatocytes were 1.92 ± 0.81% in intact liver and 1.63 ± 0.67% in culture; the frequencies of TGF
+ cells were 14.90 ± 1.9% in intact liver and 12.65 ± 0.67% in culture. This suggests that no selective loss or enrichment of GSTp+ and TGF
+ cells occurred during isolation and cultivation of the cells. Cultures were composed of all four possible categories of hepatocytes, which were present at the following percentages: GSTp/ TGF
, 89.9 ± 0.71%; GSTp/ TGF
+, 8.36 ± 1.04%; GSTp+/ TGF
, 1.05 ± 0.42%; GSTp+/ TGF
+, 0.59 ± 0.23%. Data were obtained from five animals (Figure 3A and B
).
|
DNA synthesis of hepatocytes in culture with or without expression of TGF
After 48 h in culture 63.7 ± 9.98% of all TGF+ hepatocytes showed replicative DNA synthesis, which contrasts with only 1.54 ± 0.82% of TGF
cells replicating DNA (n = 5, P < 0.0001, Wilcoxon test). Thus, the presence of TGF
is strongly associated with replicative DNA synthesis.
Addition of mature TGF to cultures exerted no additional effect on the already high DNA synthesis of TGF
+ cells (Table I
). In contrast, mature TGF
dramatically increased DNA synthesis in TGF
hepatocytes, which was blocked by the EGF receptor tyrosine kinase inhibitor tyrphostin A25, according to classical concepts of growth signal transduction. Tyrphostin A25 exerted some effect on the limited DNA replication of TGF
cells, which is indirect evidence for TGF
secretion into the medium (Table I
). In conclusion, under our conditions hepatocytes expressing TGF
have a selective growth advantage and appear insensitive to additional growth stimulation by TGF
treatment.
|
|
|
|
|
SC236 suppressed DNA synthesis selectively in GSTp+ cells in a dose-dependent manner at the 24 h time point (Figure 8). This effect was so pronounced that it decreased replication of GSTp+ cells to the low level of GSTp hepatocytes. After 48 h GSTp cells were also somewhat affected (Figure 9
). The expression of TGF
was not altered by SC236 (not shown).
|
|
Frequency of apoptosis in cultured hepatocytes
Treatment with 50 µM PGA2 increased the frequency of apoptotic hepatocytes at least 5-fold after 24 and 48 h culture, reaching significance at the later time point (controls, 0.3 ± 0.07%; PGA2, 1.62 ± 1.13%; P < 0.05, Wilcoxon's test). PGE2, PGF2, PGJ2, indomethacin and SC236 did not significantly alter the rate of apoptosis in primary hepatocyte cultures (not shown).
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
TGF as a growth factor for hepatocytes
In the present study DNA synthesis occurred almost only in cultured hepatocytes expressing TGF (Figures 4 and 6
). This coincidence of DNA replication and TGF
expression was further induced by PGE2 and PGF2
(Figure 5
). Likewise, treatment of cultures with cyproterone acetate and stimulation of regenerative or hyperplastic liver growth in intact animals increased the frequency of hepatocytes expressing TGF
and synthesizing DNA; induction of TGF
preceded induction of DNA replication and occurred in G1 of the cell cycle (submitted for publication). This is evidence that several different growth stimuli, including PGE2 and PGF2
, may act by increasing intracellular TGF
in G1.
TGF as a key determinant of growth of liver (pre)neoplasia
Preneoplastic GSTp+ cells show rates of DNA replication and of apoptosis ~3-fold higher than unaltered hepatocytes, which is evident in intact liver and in culture (Figure 4; 13,21). This finding suggests that preneoplastic hepatocytes bear an inherent defect in growth regulation that persists outside the body for at least 48 h in culture and, therefore, appears independent of intercellular contacts, endocrine or paracrine factors. The present work shows that considerably more GSTp+ cells express TGF
than do GSTp cells (Figure 4
). This may explain the intrinsic growth advantage of GSTp+ cells and supports their preneoplastic state.
In rats the expression of TGF increases further in the course of hepatocarcinogenesis, reaching peak levels in carcinoma (Figures 1 and 2
; 39,41). Human hepatocellular carcinoma and the pre-stages also show pronounced up-regulation of TGF
(38,40). This illustrates the similarity between rat and human hepatocarcinogenesis and supports the importance of TGF
for the development of liver tumours.
Possible interactions of TGF with PGE2/F2
- and PGA2/J2-induced signal transduction pathways
PGE2/F2 stimulate DNA synthesis via preferential induction of TGF
expression in TGF
-poor GSTp cells (Figure 5
); without growth stimulation these cells usually do not cycle (1921). On the other hand, PGA2/J2 suppress DNA replication in TGF
-rich hepatocytes that are mostly GSTp+ (Figure 7
); these cells often synthesize DNA and therefore go through G1. These findings are in accord with the assumed molecular modes of action of PGE2/F2
and PGA2/J2. PGE2/F2
stimulate growth via indirect activation of MAPK (36,53). The TGF
EGF receptor-induced signal transduction cascade also includes MAPK (37). Thus PGE2/F2
appear to act upstream of TGF
and to induce TGF
and TGF
-evoked transduction pathways in cells lacking this growth factor. PGA2 and PGJ2 are considered ligands for the transcription factor peroxisome proliferator-activated receptor
(PPAR
), which is expressed in hepatocytes (54). PGA2/J2 binding to a RAR/RXRPPAR
complex is accompanied by G1 arrest of the cell cycle (55). In the present study expression of TGF
remained unaffected by PGA2/J2. From these findings it may be deduced that in the growth regulatory pathway PGA2/J2 exert their effects downstream of TGF
, i.e. after TGF
had driven the cell into G1. Thus the presence or absence of TGF
seems to determine whether growth stimulating or growth inhibiting PGs become effective (Figure 10
).
|
Unlike SC236, the Cox inhibitor indomethacin failed to suppress DNA synthesis in cultured hepatocytes. These findings may be due to different effective concentrations of the two compounds, e.g. 5 µM indomethacin but only 0.005 µM SC236 are sufficient to halve the activity of purified Cox-2, while 0.1 µM indomethacin and 17 µM SC236 are required for a similar inhibition of Cox-1 (56; product information provided by Searle). Thus traces of SC236 may be sufficient and the effects of SC236 on preneoplastic hepatocytes in the present study may be attributed to a reduced activity of Cox-2. Indomethacin generally requires higher concentrations for inhibition of Cox-1 and Cox-2 and appears to abrogate PG biosynthesis only when pre-stimulated by exogenous TGF or hepatocyte growth factor (35,36,57). Furthermore, other effects of SC236 may contribute to DNA synthesis inhibition in preneoplastic hepatocytes; the structurally diverse non-steroidal anti-inflammatory drugs differ considerably in their side-effects, as has been shown by extremely variable inhibition of the activity of GSH transferases and I
B kinaseß by this class of compounds (58,59).
Implications for human liver cancer
Rodent and human hepatocellular carcinomas are rich in TGF (Figure 2
; 38,40). Anticipating analogies with preneoplastic GSTp+ cells we can put forward the following hypotheses. (i) Human liver tumours may require a basal level of PGs to proliferate; reduced PG levels due to Cox inhibition may affect growth of the tumour considerably. This was also confirmed by an anti-proliferative effect of the Cox-2 inhibitor sulindac on human hepatocellular carcinoma cell lines (60). (ii) Tumour cells expressing TGF
may not require elevated activities of Cox enzymes, leading to high intracellular concentrations of both PGE2/F2
and PGA2/J2. PGE2/F2
may not stimulate additional growth of tumours with already accelerated cell replication, rather, the tumour cells would be in danger of growth inhibition by PGA2/J2. These assumptions are consistent with the observation that liver tumours do not overexpress the two Cox isoenzymes and even tend to exhibit decreased expression, as shown in the present and in previous studies on rats and humans (61,62). It remains to be elucidated whether tumours with elevated levels of PGE2 and PGF2
are poor in TGF
.
This study demonstrates differential effects of TGF, PGs and Cox inhibitors on normal and preneoplastic hepatocytes. For tumour prevention and therapy it seems promising to focus future studies on these differences.
![]() |
Notes |
---|
![]() |
Acknowledgments |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|